Amgen and UCB’s Evenity (romosozumab) Receive EC’s Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

 Amgen and UCB’s Evenity (romosozumab) Receive EC’s Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Amgen and UCB’s Evenity (romosozumab) Receive EC’s Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Shots:

  • The EC has granted MAA to Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture, following the CHMP’s positive opinion received in Oct’2019
  • Evenity is the first osteoporosis therapy to be approved by EC since 2010 and the MAA will be valid in EU and EEA- EFTA states (Norway, Iceland and Liechtenstein)
  • Evenity is a bone-forming mAb with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss) with its expected availability in EEA in H1’20

Click here to­ read full press release/ article | Ref: Amgen | Image: STAT News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post